REGULATORY

Trodelvy Up for Japan Panel Review on Sept. 12, Meiji COVID Jab on Agenda Too

September 6, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A key Japanese health ministry panel will discuss on September 12 whether to recommend approval for Gilead Sciences’ antibody drug conjugate (ADC) sacituzumab govitecan, otherwise known as Trodelvy in the US and Europe. The Pharmaceutical Affairs Council’s Second Committee on…

To read the full story

Gilead Files Trodelvy for Triple-Negative Breast Cancer in Japan
January 31, 2024

REGULATORY

Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…